.
MergerLinks Header Logo

New Deal


Announced

PerkinElmer to acquire Cisbio Bioassays

Financials

Edit Data
Transaction Value-
Consideration Type-
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

drug discovery & manufacturing

Acquisition

Private

Pending

biomarkers

cytokines

invitro

in vitro diagnostics

Natural

drug discovery

Majority

Private Equity

France

Medical Services

Single Bidder

Synopsis

Edit

Abénex and Cisbio's management sold their direct and indirect stake in Cisbio Bioassays to PerkinElmer. As a result of these transactions, PerkinElmer owns 100% of Cisbio Bioassays. Financial terms were not disclosed. Cisbio has become a leading Life Sciences company which develops, manufactures, and markets high quality kits and reagents for the drug discovery and life science markets used by pharmaceutical, biotechnology, academia and contract research organizations across the globe. The addition of Cisbio’s capabilities to PerkinElmer will enable life science researchers to have access to assay tools that address the broad diversity of target types and biological configurations, for both small molecule and biologic drug discovery.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US